Loading stock data…
PODD
$159.61+8.10 (+5.35%)
Market ClosedLast close Jun 9
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Insulet Corporation in the Healthcare sector is trading at $159.61 with a market capitalization of $10.0B. Wall Street consensus targets $243.78 (23 analysts), implying a +52.7% move over the next 12 months. The stock is currently near its 52-week low of $140.63, remaining 39.3% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +52.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$159.61
Potential Upside
56.8%
Whystock Fair Value$250.35
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus23 analysts
Mean target$243.78+52.7%
Range$165.00 – $360.00
Fundamentals
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin de...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$10.04B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
33.94
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.20
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
23.25%
Volume
Today's trading volume
1.82M
Recent News
Insulet (PODD) Enhances Omnipod 5 System with New Target Glucose Option
Insulet Corporation (NASDAQ:PODD) is one of the oversold stocks to buy right now. On June 3, Insulet launched significant enhancements to its Omnipod 5 Automated Insulin Delivery/AID System in the US, featuring a new 100 mg/dL Target Glucose option. This update allows for greater personalization and improved glycemic control, enabling users to increase their time […]
Why Is Insulet (PODD) Down 8.7% Since Last Earnings Report?
Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Dexcom buys Nutrisense; Insulet rolls out patch pump update
In the lead-up to the American Diabetes Association’s Scientific Sessions, Dexcom announced an acquisition and Insulet improved the software for its latest patch pump.
Is Omnipod 5’s Algorithm and Libre 3 Plus Upgrade Altering The Investment Case For Insulet (PODD)?
In early June 2026, Insulet began rolling out FDA-cleared algorithm enhancements to its Omnipod 5 Automated Insulin Delivery System in the U.S., adding a 100 mg/dL target option and new compatibility with Abbott’s Libre 3 Plus sensor via over-the-air updates and newly shipped Pods. This combination of tighter glucose personalization, improved automated mode performance, and broader sensor choice strengthens Omnipod 5’s appeal for both patients and clinicians even as the company manages...
3 Reasons We’re Fans of Insulet (PODD)
Shareholders of Insulet would probably like to forget the past six months even happened. The stock dropped 54.4% and now trades at $144.10. This might have investors contemplating their next move.